Clinical Trial Update: RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating RGI-2001 to prevent acute graft-versus-host disease in patients after allogeneic hematopoietic stem cell transplantation has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• RGI-2001

Snippet

Sponsor: Regimmune Corporation | Conditions: Graft Vs Host Disease, Graft-versus-host-disease | Phase 2 | Status: COMPLETED | Results posted: 2024-04-17